Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen

H. Kobayashi, M. Wood, Y. Song, E. Appella, Esteban Celis

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

It is accepted that both helper and CTLs play a critical role in immune antitumor responses. Thus, the design of effective immune-based therapies for cancer relies in the identification of relevant tumor-associated antigens (TAAs) capable of eliciting strong helper and cytotoxic T-cell responses against tumor cells. The product of the HER2/neu oncogene is considered as a prototype TAA, because it is found overexpressed in a large variety of malignancies, whereas normal cells only produce low levels of this product. Several cytotoxic T-cell epitopes for HER2/neu have been identified that enable the design of peptide-based therapeutic vaccines for tumors expressing this TAA. Nevertheless, it is expected that inclusion of peptide epitopes capable of eliciting HER2/neu-specific T helper responses into these vaccines may enhance their effectiveness in the clinic. We describe here a strategy to identify helper T-cell epitopes for HER2/neu that focuses on peptides predicted to bind to numerous histo-compatibility alleles (promiscuous epitopes), which would encourage their use in therapeutic vaccines for the general cancer patient population. Following this approach, we successfully identified several peptides that elicited T helper (CD4+) proliferative responses to peptides derived from HER2/neu. Most of the T-cell responses appeared to reflect a low affinity for antigen, which could be the result of immune tolerance because HER2/neu is expressed in low levels in normal cells and possibly including lymphocytes and monocytes. Interestingly, one of these peptides, HER2883, was recognized by T cells in the context of either HLA-DR1, HLA-DR4, HLA-DR52, and HLA-DR53, indicating a high degree of histocompatibility promiscuity. Furthermore, T cells that reacted with peptide HER2883 could also recognize antigen-presenting cells that process HER2/neu recombinant protein. These results may be relevant for the design of more effective therapeutic vaccines for tumors expressing the HER2/neu oncogene product.

Original languageEnglish (US)
Pages (from-to)5228-5236
Number of pages9
JournalCancer Research
Volume60
Issue number18
StatePublished - Sep 15 2000
Externally publishedYes

Fingerprint

T-Lymphocyte Epitopes
Neoplasm Antigens
Helper-Inducer T-Lymphocytes
Peptides
Cancer Vaccines
T-Lymphocytes
Epitopes
HLA-DR1 Antigen
HLA-DR4 Antigen
Peptide T
Neoplasms
Immune Tolerance
Histocompatibility
Oncogene Proteins
Therapeutic Uses
Antigen-Presenting Cells
Oncogenes
Recombinant Proteins
Monocytes
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kobayashi, H., Wood, M., Song, Y., Appella, E., & Celis, E. (2000). Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Research, 60(18), 5228-5236.

Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. / Kobayashi, H.; Wood, M.; Song, Y.; Appella, E.; Celis, Esteban.

In: Cancer Research, Vol. 60, No. 18, 15.09.2000, p. 5228-5236.

Research output: Contribution to journalArticle

Kobayashi, H, Wood, M, Song, Y, Appella, E & Celis, E 2000, 'Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen', Cancer Research, vol. 60, no. 18, pp. 5228-5236.
Kobayashi, H. ; Wood, M. ; Song, Y. ; Appella, E. ; Celis, Esteban. / Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. In: Cancer Research. 2000 ; Vol. 60, No. 18. pp. 5228-5236.
@article{40479a1bfb0d420aa5d2b85d5113845d,
title = "Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen",
abstract = "It is accepted that both helper and CTLs play a critical role in immune antitumor responses. Thus, the design of effective immune-based therapies for cancer relies in the identification of relevant tumor-associated antigens (TAAs) capable of eliciting strong helper and cytotoxic T-cell responses against tumor cells. The product of the HER2/neu oncogene is considered as a prototype TAA, because it is found overexpressed in a large variety of malignancies, whereas normal cells only produce low levels of this product. Several cytotoxic T-cell epitopes for HER2/neu have been identified that enable the design of peptide-based therapeutic vaccines for tumors expressing this TAA. Nevertheless, it is expected that inclusion of peptide epitopes capable of eliciting HER2/neu-specific T helper responses into these vaccines may enhance their effectiveness in the clinic. We describe here a strategy to identify helper T-cell epitopes for HER2/neu that focuses on peptides predicted to bind to numerous histo-compatibility alleles (promiscuous epitopes), which would encourage their use in therapeutic vaccines for the general cancer patient population. Following this approach, we successfully identified several peptides that elicited T helper (CD4+) proliferative responses to peptides derived from HER2/neu. Most of the T-cell responses appeared to reflect a low affinity for antigen, which could be the result of immune tolerance because HER2/neu is expressed in low levels in normal cells and possibly including lymphocytes and monocytes. Interestingly, one of these peptides, HER2883, was recognized by T cells in the context of either HLA-DR1, HLA-DR4, HLA-DR52, and HLA-DR53, indicating a high degree of histocompatibility promiscuity. Furthermore, T cells that reacted with peptide HER2883 could also recognize antigen-presenting cells that process HER2/neu recombinant protein. These results may be relevant for the design of more effective therapeutic vaccines for tumors expressing the HER2/neu oncogene product.",
author = "H. Kobayashi and M. Wood and Y. Song and E. Appella and Esteban Celis",
year = "2000",
month = "9",
day = "15",
language = "English (US)",
volume = "60",
pages = "5228--5236",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen

AU - Kobayashi, H.

AU - Wood, M.

AU - Song, Y.

AU - Appella, E.

AU - Celis, Esteban

PY - 2000/9/15

Y1 - 2000/9/15

N2 - It is accepted that both helper and CTLs play a critical role in immune antitumor responses. Thus, the design of effective immune-based therapies for cancer relies in the identification of relevant tumor-associated antigens (TAAs) capable of eliciting strong helper and cytotoxic T-cell responses against tumor cells. The product of the HER2/neu oncogene is considered as a prototype TAA, because it is found overexpressed in a large variety of malignancies, whereas normal cells only produce low levels of this product. Several cytotoxic T-cell epitopes for HER2/neu have been identified that enable the design of peptide-based therapeutic vaccines for tumors expressing this TAA. Nevertheless, it is expected that inclusion of peptide epitopes capable of eliciting HER2/neu-specific T helper responses into these vaccines may enhance their effectiveness in the clinic. We describe here a strategy to identify helper T-cell epitopes for HER2/neu that focuses on peptides predicted to bind to numerous histo-compatibility alleles (promiscuous epitopes), which would encourage their use in therapeutic vaccines for the general cancer patient population. Following this approach, we successfully identified several peptides that elicited T helper (CD4+) proliferative responses to peptides derived from HER2/neu. Most of the T-cell responses appeared to reflect a low affinity for antigen, which could be the result of immune tolerance because HER2/neu is expressed in low levels in normal cells and possibly including lymphocytes and monocytes. Interestingly, one of these peptides, HER2883, was recognized by T cells in the context of either HLA-DR1, HLA-DR4, HLA-DR52, and HLA-DR53, indicating a high degree of histocompatibility promiscuity. Furthermore, T cells that reacted with peptide HER2883 could also recognize antigen-presenting cells that process HER2/neu recombinant protein. These results may be relevant for the design of more effective therapeutic vaccines for tumors expressing the HER2/neu oncogene product.

AB - It is accepted that both helper and CTLs play a critical role in immune antitumor responses. Thus, the design of effective immune-based therapies for cancer relies in the identification of relevant tumor-associated antigens (TAAs) capable of eliciting strong helper and cytotoxic T-cell responses against tumor cells. The product of the HER2/neu oncogene is considered as a prototype TAA, because it is found overexpressed in a large variety of malignancies, whereas normal cells only produce low levels of this product. Several cytotoxic T-cell epitopes for HER2/neu have been identified that enable the design of peptide-based therapeutic vaccines for tumors expressing this TAA. Nevertheless, it is expected that inclusion of peptide epitopes capable of eliciting HER2/neu-specific T helper responses into these vaccines may enhance their effectiveness in the clinic. We describe here a strategy to identify helper T-cell epitopes for HER2/neu that focuses on peptides predicted to bind to numerous histo-compatibility alleles (promiscuous epitopes), which would encourage their use in therapeutic vaccines for the general cancer patient population. Following this approach, we successfully identified several peptides that elicited T helper (CD4+) proliferative responses to peptides derived from HER2/neu. Most of the T-cell responses appeared to reflect a low affinity for antigen, which could be the result of immune tolerance because HER2/neu is expressed in low levels in normal cells and possibly including lymphocytes and monocytes. Interestingly, one of these peptides, HER2883, was recognized by T cells in the context of either HLA-DR1, HLA-DR4, HLA-DR52, and HLA-DR53, indicating a high degree of histocompatibility promiscuity. Furthermore, T cells that reacted with peptide HER2883 could also recognize antigen-presenting cells that process HER2/neu recombinant protein. These results may be relevant for the design of more effective therapeutic vaccines for tumors expressing the HER2/neu oncogene product.

UR - http://www.scopus.com/inward/record.url?scp=0034665130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034665130&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 5228

EP - 5236

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 18

ER -